메뉴 건너뛰기




Volumn 41, Issue 7-8, 2007, Pages 1144-1152

Oral oxymorphone for pain management

Author keywords

Chronic pain; Oxymorphone

Indexed keywords

ANESTHETIC AGENT; ANTIDEPRESSANT AGENT; BUPRENORPHINE; BUTORPHANOL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETIDINE; CODEINE; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DELTA OPIATE RECEPTOR; HYDROCODONE; HYDROMORPHONE; HYPNOTIC AGENT; METHADONE; MORPHINE; MU OPIATE RECEPTOR; NALOXONE; OPANA; OPANA ER; OPIATE AGONIST; OXYCODONE; OXYMORPHONE; PHENOTHIAZINE DERIVATIVE; PLACEBO; SEDATIVE AGENT; TIMERX; UNCLASSIFIED DRUG;

EID: 34547201492     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H451     Document Type: Review
Times cited : (28)

References (30)
  • 1
    • 34547145776 scopus 로고    scopus 로고
    • Merriam-Webster Online Dictionary. www.m-w.com/dictionary/pain (accessed 2006 Aug 1).
    • Merriam-Webster Online Dictionary. www.m-w.com/dictionary/pain (accessed 2006 Aug 1).
  • 2
    • 0016227011 scopus 로고
    • A historical-phenomenological study of bodily pain in Western man
    • De Moulin D. A historical-phenomenological study of bodily pain in Western man. Bull Hist Med 1974;48:540-69.
    • (1974) Bull Hist Med , vol.48 , pp. 540-569
    • De Moulin, D.1
  • 3
    • 34547172229 scopus 로고    scopus 로고
    • Milton J. Paradise lost. New York: Norton WW & Company, Inc., 2004 (original 1666).
    • Milton J. Paradise lost. New York: Norton WW & Company, Inc., 2004 (original 1666).
  • 5
    • 0022523784 scopus 로고
    • Classification of chronic pain: Descriptions of chronic pain syndromes and definitions of pain terms
    • International Association for the Study of Pain
    • International Association for the Study of Pain. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. Pain 1986;3(suppl):S1-225.
    • (1986) Pain , vol.3 , Issue.SUPPL.
  • 6
    • 0003882050 scopus 로고    scopus 로고
    • Cancer pain relief and palliative care
    • World Health Organization, Committee, 3rd ed. WHO: Geneva
    • World Health Organization. Cancer pain relief and palliative care: Report of WHO Expert Committee, 3rd ed. WHO: Geneva, 1996.
    • (1996) Report of WHO Expert
  • 7
    • 34547186627 scopus 로고    scopus 로고
    • : Endogenous opioids
    • Warfield CA, Fausett HJ, eds, 2nd ed. New York: Lippincott Williams & Wilkins
    • Stranc DS. Chapter 3: endogenous opioids. In: Warfield CA, Fausett HJ, eds. Manual of pain management. 2nd ed. New York: Lippincott Williams & Wilkins, 2002.
    • (2002) Manual of pain management
    • Stranc, D.S.1
  • 8
    • 34547146430 scopus 로고    scopus 로고
    • FDA OKs the pain drug Opana: prescription drug is oral form of painkiller that used to be injection-only. WebMD. www.webmd.com/content/article/124/ 115549.htm (accessed 2006 Aug 1).
    • FDA OKs the pain drug Opana: prescription drug is oral form of painkiller that used to be injection-only. WebMD. www.webmd.com/content/article/124/ 115549.htm (accessed 2006 Aug 1).
  • 9
    • 12144289451 scopus 로고    scopus 로고
    • Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydromorphone]
    • Ananthan S, Khare NK, Saini SK, et al. Identification of opioid ligands possessing mixed micro agonist/delta antagonist activity among pyridomorphinans derived from naloxone, oxymorphone, and hydromorphone [correction of hydromorphone]. J Med Chem 2004;47:1400-12.
    • (2004) J Med Chem , vol.47 , pp. 1400-1412
    • Ananthan, S.1    Khare, N.K.2    Saini, S.K.3
  • 10
    • 34547155210 scopus 로고    scopus 로고
    • Package insert. Opana oxymorphone hydrochloride, Chadds Ford, PA: Endo Pharmaceuticals Inc, Jun 2006
    • Package insert. Opana (oxymorphone hydrochloride). Chadds Ford, PA: Endo Pharmaceuticals Inc, Jun 2006.
  • 11
    • 34547162959 scopus 로고    scopus 로고
    • Package insert. Opana ER oxymorphone hydrochloride extended-release, Chadds Ford, PA: Endo Pharmaceuticals Inc, June 2006
    • Package insert. Opana ER (oxymorphone hydrochloride extended-release). Chadds Ford, PA: Endo Pharmaceuticals Inc, June 2006.
  • 13
    • 1842480273 scopus 로고    scopus 로고
    • Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: Results of a randomized crossover study
    • Adams MP, Ahdieh H. Pharmacokinetics and dose-proportionality of oxymorphone extended release and its metabolites: results of a randomized crossover study. Pharmacotherapy 2004;24:468-76.
    • (2004) Pharmacotherapy , vol.24 , pp. 468-476
    • Adams, M.P.1    Ahdieh, H.2
  • 14
    • 0037369176 scopus 로고    scopus 로고
    • Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: Theory and clinical reality, part I
    • Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 2003;44:167-71.
    • (2003) Psychosomatics , vol.44 , pp. 167-171
    • Armstrong, S.C.1    Cozza, K.L.2
  • 15
    • 16844377997 scopus 로고    scopus 로고
    • Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways
    • Adams M, Pieniaszek HJ. Oxymorphone extended release does not affect CYP2C9 or CYP3A4 metabolic pathways. J Clin Pharmacol 2005; 45:337-45.
    • (2005) J Clin Pharmacol , vol.45 , pp. 337-345
    • Adams, M.1    Pieniaszek, H.J.2
  • 16
    • 28844473848 scopus 로고    scopus 로고
    • Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: Results of a randomized, double-blind, placebo-controlled trial
    • Gimbel JS, Walker D, Ma T, Ahdieh H. Efficacy and safety of oxymorphone immediate release for the treatment of mild to moderate pain after ambulatory orthopedic surgery: results of a randomized, double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2005;86:2284-9.
    • (2005) Arch Phys Med Rehabil , vol.86 , pp. 2284-2289
    • Gimbel, J.S.1    Walker, D.2    Ma, T.3    Ahdieh, H.4
  • 17
    • 13244272132 scopus 로고    scopus 로고
    • Effectiveness and safety of oral extended release oxymorphone for the treatment of cancer pain: A pilot study
    • Sloan P, Slatkin N, Ahdieh H. Effectiveness and safety of oral extended release oxymorphone for the treatment of cancer pain: a pilot study. Support Care Cancer 2005;13:57-65.
    • (2005) Support Care Cancer , vol.13 , pp. 57-65
    • Sloan, P.1    Slatkin, N.2    Ahdieh, H.3
  • 18
    • 28444472350 scopus 로고    scopus 로고
    • Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: Results of a randomized, double-blind, placebo- and active-controlled Phase III trial
    • Matsumoto AK, Babul N, Ahdieh H. Oxymorphone extended-release tablets relieve moderate to severe pain and improve physical function in osteoarthritis: results of a randomized, double-blind, placebo- and active-controlled Phase III trial. Pain Med 2005;6:357-66.
    • (2005) Pain Med , vol.6 , pp. 357-366
    • Matsumoto, A.K.1    Babul, N.2    Ahdieh, H.3
  • 19
    • 2942640367 scopus 로고    scopus 로고
    • Efficacy of oxymorphone extended release in postsurgical pain: A randomized clinical trial in knee arthroplasty
    • Ahdieh H, Ma T, Babul N, Lee D. Efficacy of oxymorphone extended release in postsurgical pain: a randomized clinical trial in knee arthroplasty. J Clin Pharmacol 2004;44:767-76.
    • (2004) J Clin Pharmacol , vol.44 , pp. 767-776
    • Ahdieh, H.1    Ma, T.2    Babul, N.3    Lee, D.4
  • 20
    • 17144390270 scopus 로고    scopus 로고
    • Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: A one-year study
    • McIlwain H, Ahdieh H. Safety, tolerability, and effectiveness of oxymorphone extended release for moderate to severe osteoarthritis pain: a one-year study. Am J Ther 2005;12:106-12.
    • (2005) Am J Ther , vol.12 , pp. 106-112
    • McIlwain, H.1    Ahdieh, H.2
  • 21
    • 6444221477 scopus 로고    scopus 로고
    • The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain
    • Gimbel J, Ahdieh H. The efficacy and safety of oral immediate-release oxymorphone for postsurgical pain. Anesth Analg 2004;99:1472-7.
    • (2004) Anesth Analg , vol.99 , pp. 1472-1477
    • Gimbel, J.1    Ahdieh, H.2
  • 22
    • 0037626715 scopus 로고    scopus 로고
    • Oxymorphone-Endo/Penwest: EN 3202, EN 3203. Drugs R D 2003;4: 204-6.
    • Oxymorphone-Endo/Penwest: EN 3202, EN 3203. Drugs R D 2003;4: 204-6.
  • 23
    • 84858086550 scopus 로고    scopus 로고
    • Penwest. Patterson, NY. Gamma scintigraphy imaging and pharmacokinetic analysis of extended release TIMERx technology (abstract 831)
    • Presented at:, Vancouver, BC, Canada, May 6-9, accessed Jul 26
    • Baichwal A, Staniforth J, Adams M, Ahdieh H. Penwest. Patterson, NY. Gamma scintigraphy imaging and pharmacokinetic analysis of extended release TIMERx technology (abstract 831). Presented at: American Pain Society Annual Meeting, Vancouver, BC, Canada, May 6-9, 2004. www.ampainsoc.org/db2/abstract/ view?poster_id=2123#831 (accessed 2006 Jul 26).
    • (2004) American Pain Society Annual Meeting
    • Baichwal, A.1    Staniforth, J.2    Adams, M.3    Ahdieh, H.4
  • 24
    • 84858099956 scopus 로고    scopus 로고
    • Penwest Pharmaceuticals Co, accessed 2006 Aug 3
    • Penwest Pharmaceuticals Co. 2006. www.penwest.com/timerx_description. html (accessed 2006 Aug 3).
    • (2006)
  • 25
    • 32444442890 scopus 로고    scopus 로고
    • Psychostimulants and delirium in patients receiving palliative care
    • Keen JC, Brown D. Psychostimulants and delirium in patients receiving palliative care. Palliat Support Care 2004;2:199-202.
    • (2004) Palliat Support Care , vol.2 , pp. 199-202
    • Keen, J.C.1    Brown, D.2
  • 28
    • 34547182931 scopus 로고    scopus 로고
    • Package insert. MS Contin morphine sulfate controlled-release, Stamford, CT: Purdue Pharma LP, Jun 2005
    • Package insert. MS Contin (morphine sulfate controlled-release). Stamford, CT: Purdue Pharma LP, Jun 2005.
  • 29
    • 3042595723 scopus 로고    scopus 로고
    • Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: A randomized controlled study
    • Jun 1;
    • Gabrail N, Dvergsten C, Ahdieh H. Establishing the dosage equivalency of oxymorphone extended release and oxycodone controlled release in patients with cancer pain: a randomized controlled study. Curr Med Res Opin 2004 Jun 1;20:911-8.
    • (2004) Curr Med Res Opin , vol.20 , pp. 911-918
    • Gabrail, N.1    Dvergsten, C.2    Ahdieh, H.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.